Lyvup is a platform company, not a consultancy. Our advisory services exist as an extension of active research and development — grounded in clinical projects, validated methodologies, and direct experience building and deploying digital health platforms. We advise on what we practice.
Digital health advisory is a crowded field. Strategy consultants can describe the landscape. Academic researchers can review the literature. What is rarer — and considerably more valuable — is an organisation that is simultaneously building clinical-grade platforms, coordinating European research projects, and working through the real implementation challenges of integrating AI, sensors, and behavioral science into care pathways.
That is the position from which Lyvup advises. The methodologies we apply for clients are the same ones we test and validate in our own research programmes. The questions we help partners navigate are questions we have navigated ourselves.
Each service is scoped to the specific context and objectives of the partner organisation. We do not offer standardised packages — engagements are designed around the actual question, not a predetermined format.
For pharmaceutical companies seeking to improve therapeutic outcomes through evidence-based patient support — beyond alerts and reminder systems.
Most pharmaceutical patient support programmes are designed around operational convenience rather than behavioral effectiveness. They send reminders at fixed intervals, deliver generic educational content, and measure engagement through proxy metrics that correlate poorly with long-term adherence. Lyvup helps pharmaceutical partners redesign these programmes from the ground up — using the same behavioral science principles and intervention architectures that underpin our own clinical platforms.
This includes defining the intervention logic, establishing appropriate measurement frameworks, advising on real-world evidence generation, and providing input on the clinical and regulatory positioning of digital companion tools.
For digital health companies outside Europe navigating the regulatory, clinical, and commercial requirements of entering the European market.
The European digital therapeutics landscape is structurally different from the US or Asian markets: the MDR regulatory framework, fragmented national reimbursement pathways, the centrality of academic and clinical partnerships in establishing credibility, and the distinct procurement dynamics of European health systems all require specific knowledge that is difficult to acquire without direct experience.
Lyvup advises non-European digital health companies on what is actually required to enter this market — from clinical validation strategy and partner selection to regulatory positioning and go-to-market sequencing. This is practical guidance drawn from operating within European health research infrastructure, not theoretical market mapping.
For organisations with existing digital health products that underperform on long-term engagement, adherence, or behavior change outcomes.
The majority of digital health products are designed by engineers and designers who understand user experience but have limited grounding in behavioral psychology. The result is products that perform well in short-term trials and poorly in long-term real-world use. The gap between clinical efficacy and real-world effectiveness is almost always a behavioral gap — not a technical one.
Lyvup conducts structured reviews of digital health products against established principles of behavioral science: how interventions are timed and contextualised, how motivational profiles are identified and addressed, how engagement architectures are structured for sustained use rather than initial adoption, and how the product's implicit behavioral model aligns — or fails to align — with what is known about sustained behavior change in clinical populations.
All engagements follow a consistent approach — scoped tightly, delivered within a defined timeframe, with a concrete output at each stage.
A structured intake conversation to understand the specific challenge, the organisational context, and what a useful outcome looks like. We do not begin work until the scope is clearly defined and mutually agreed.
Depending on the engagement type, this involves reviewing existing products, data, programme documentation, or clinical evidence — applying Lyvup's frameworks and drawing on current research where relevant.
Every engagement produces a written deliverable — a structured report, framework, or strategic recommendation — that can be acted on independently of continued Lyvup involvement.
Where appropriate, Lyvup can support implementation of recommendations through ongoing advisory — or, where the work reveals a natural fit, through a deeper research or product partnership.